First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics

Katherine A. Rauen, Abeer Alsaegh, Shay Ben-Shachar, Yemima Berman, Jaishri Blakeley, Isabel Cordeiro, Ype Elgersma, D. Gareth Evans, Michael J. Fisher, Ian M. Frayling, Joshi George, Susan M. Huson, Bronwyn Kerr, Uday Khire, Bruce Korf, Eric Legius, Ludwine Messiaen, Rick van Minkelen, Sheela Nampoothiri, Joanne NgeowLuis F. Parada, Shubha Phadke, Ashok Pillai, Scott R. Plotkin, Ratna Puri, Anup Raji, Vijaya Ramesh, Nancy Ratner, Suma P. Shankar, Sheetal Sharda, Anant Tambe, Miikka Vikkula, Brigitte C. Widemann, Pierre Wolkenstein, Meena Upadhyaya

Research output: Contribution to journalArticle

Abstract

The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndromes caused by germline mutations in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) pathway. The RASopathies include NF1, Noonan syndrome, Noonan syndrome with multiple lentigines, Costello syndrome, cardio-facio-cutaneous syndrome, Legius syndrome, capillary malformation arterio-venous malformation syndrome, and SYNGAP1 autism. Due to their common underlying pathogenetic etiology, all these syndromes have significant phenotypic overlap of which one common feature include a predisposition to tumors, which may be benign or malignant. Together as a group, they represent one of the most common multiple congenital anomaly syndromes estimating to affect approximately one in 1000 individuals worldwide. The subcontinent of India represents one of the largest populations in the world, yet remains underserved from an aspect of clinical genetics services. In an effort to bridge this gap, the First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and Advances of New Therapeutics was held in Kochi, Kerala, India. These proceedings chronicle this timely and topical international symposium directed at discussing the best practices and therapies for individuals with neurofibromatoses and RASopathies.

Original languageEnglish (US)
Pages (from-to)1091-1097
Number of pages7
JournalAmerican Journal of Medical Genetics, Part A
Volume179
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Neurofibromatoses
LEOPARD Syndrome
Neurofibromatosis 1
India
Costello Syndrome
Genetic Services
Noonan Syndrome
Neurofibromatosis 2
Gene Components
Therapeutics
Germ-Line Mutation
Autistic Disorder
Mitogen-Activated Protein Kinases
Practice Guidelines
Nervous System
Neoplasms
Growth
Population

Keywords

  • clinical trial
  • neurofibromatoses
  • RASopathy
  • signal transduction pathway
  • therapy

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

First International Conference on RASopathies and Neurofibromatoses in Asia : Identification and advances of new therapeutics. / Rauen, Katherine A.; Alsaegh, Abeer; Ben-Shachar, Shay; Berman, Yemima; Blakeley, Jaishri; Cordeiro, Isabel; Elgersma, Ype; Evans, D. Gareth; Fisher, Michael J.; Frayling, Ian M.; George, Joshi; Huson, Susan M.; Kerr, Bronwyn; Khire, Uday; Korf, Bruce; Legius, Eric; Messiaen, Ludwine; van Minkelen, Rick; Nampoothiri, Sheela; Ngeow, Joanne; Parada, Luis F.; Phadke, Shubha; Pillai, Ashok; Plotkin, Scott R.; Puri, Ratna; Raji, Anup; Ramesh, Vijaya; Ratner, Nancy; Shankar, Suma P.; Sharda, Sheetal; Tambe, Anant; Vikkula, Miikka; Widemann, Brigitte C.; Wolkenstein, Pierre; Upadhyaya, Meena.

In: American Journal of Medical Genetics, Part A, Vol. 179, No. 6, 01.06.2019, p. 1091-1097.

Research output: Contribution to journalArticle

Rauen, KA, Alsaegh, A, Ben-Shachar, S, Berman, Y, Blakeley, J, Cordeiro, I, Elgersma, Y, Evans, DG, Fisher, MJ, Frayling, IM, George, J, Huson, SM, Kerr, B, Khire, U, Korf, B, Legius, E, Messiaen, L, van Minkelen, R, Nampoothiri, S, Ngeow, J, Parada, LF, Phadke, S, Pillai, A, Plotkin, SR, Puri, R, Raji, A, Ramesh, V, Ratner, N, Shankar, SP, Sharda, S, Tambe, A, Vikkula, M, Widemann, BC, Wolkenstein, P & Upadhyaya, M 2019, 'First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics', American Journal of Medical Genetics, Part A, vol. 179, no. 6, pp. 1091-1097. https://doi.org/10.1002/ajmg.a.61125
Rauen, Katherine A. ; Alsaegh, Abeer ; Ben-Shachar, Shay ; Berman, Yemima ; Blakeley, Jaishri ; Cordeiro, Isabel ; Elgersma, Ype ; Evans, D. Gareth ; Fisher, Michael J. ; Frayling, Ian M. ; George, Joshi ; Huson, Susan M. ; Kerr, Bronwyn ; Khire, Uday ; Korf, Bruce ; Legius, Eric ; Messiaen, Ludwine ; van Minkelen, Rick ; Nampoothiri, Sheela ; Ngeow, Joanne ; Parada, Luis F. ; Phadke, Shubha ; Pillai, Ashok ; Plotkin, Scott R. ; Puri, Ratna ; Raji, Anup ; Ramesh, Vijaya ; Ratner, Nancy ; Shankar, Suma P. ; Sharda, Sheetal ; Tambe, Anant ; Vikkula, Miikka ; Widemann, Brigitte C. ; Wolkenstein, Pierre ; Upadhyaya, Meena. / First International Conference on RASopathies and Neurofibromatoses in Asia : Identification and advances of new therapeutics. In: American Journal of Medical Genetics, Part A. 2019 ; Vol. 179, No. 6. pp. 1091-1097.
@article{ecf3ef53905347e6a42a63a47e089b82,
title = "First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics",
abstract = "The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndromes caused by germline mutations in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) pathway. The RASopathies include NF1, Noonan syndrome, Noonan syndrome with multiple lentigines, Costello syndrome, cardio-facio-cutaneous syndrome, Legius syndrome, capillary malformation arterio-venous malformation syndrome, and SYNGAP1 autism. Due to their common underlying pathogenetic etiology, all these syndromes have significant phenotypic overlap of which one common feature include a predisposition to tumors, which may be benign or malignant. Together as a group, they represent one of the most common multiple congenital anomaly syndromes estimating to affect approximately one in 1000 individuals worldwide. The subcontinent of India represents one of the largest populations in the world, yet remains underserved from an aspect of clinical genetics services. In an effort to bridge this gap, the First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and Advances of New Therapeutics was held in Kochi, Kerala, India. These proceedings chronicle this timely and topical international symposium directed at discussing the best practices and therapies for individuals with neurofibromatoses and RASopathies.",
keywords = "clinical trial, neurofibromatoses, RASopathy, signal transduction pathway, therapy",
author = "Rauen, {Katherine A.} and Abeer Alsaegh and Shay Ben-Shachar and Yemima Berman and Jaishri Blakeley and Isabel Cordeiro and Ype Elgersma and Evans, {D. Gareth} and Fisher, {Michael J.} and Frayling, {Ian M.} and Joshi George and Huson, {Susan M.} and Bronwyn Kerr and Uday Khire and Bruce Korf and Eric Legius and Ludwine Messiaen and {van Minkelen}, Rick and Sheela Nampoothiri and Joanne Ngeow and Parada, {Luis F.} and Shubha Phadke and Ashok Pillai and Plotkin, {Scott R.} and Ratna Puri and Anup Raji and Vijaya Ramesh and Nancy Ratner and Shankar, {Suma P.} and Sheetal Sharda and Anant Tambe and Miikka Vikkula and Widemann, {Brigitte C.} and Pierre Wolkenstein and Meena Upadhyaya",
year = "2019",
month = "6",
day = "1",
doi = "10.1002/ajmg.a.61125",
language = "English (US)",
volume = "179",
pages = "1091--1097",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - First International Conference on RASopathies and Neurofibromatoses in Asia

T2 - Identification and advances of new therapeutics

AU - Rauen, Katherine A.

AU - Alsaegh, Abeer

AU - Ben-Shachar, Shay

AU - Berman, Yemima

AU - Blakeley, Jaishri

AU - Cordeiro, Isabel

AU - Elgersma, Ype

AU - Evans, D. Gareth

AU - Fisher, Michael J.

AU - Frayling, Ian M.

AU - George, Joshi

AU - Huson, Susan M.

AU - Kerr, Bronwyn

AU - Khire, Uday

AU - Korf, Bruce

AU - Legius, Eric

AU - Messiaen, Ludwine

AU - van Minkelen, Rick

AU - Nampoothiri, Sheela

AU - Ngeow, Joanne

AU - Parada, Luis F.

AU - Phadke, Shubha

AU - Pillai, Ashok

AU - Plotkin, Scott R.

AU - Puri, Ratna

AU - Raji, Anup

AU - Ramesh, Vijaya

AU - Ratner, Nancy

AU - Shankar, Suma P.

AU - Sharda, Sheetal

AU - Tambe, Anant

AU - Vikkula, Miikka

AU - Widemann, Brigitte C.

AU - Wolkenstein, Pierre

AU - Upadhyaya, Meena

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndromes caused by germline mutations in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) pathway. The RASopathies include NF1, Noonan syndrome, Noonan syndrome with multiple lentigines, Costello syndrome, cardio-facio-cutaneous syndrome, Legius syndrome, capillary malformation arterio-venous malformation syndrome, and SYNGAP1 autism. Due to their common underlying pathogenetic etiology, all these syndromes have significant phenotypic overlap of which one common feature include a predisposition to tumors, which may be benign or malignant. Together as a group, they represent one of the most common multiple congenital anomaly syndromes estimating to affect approximately one in 1000 individuals worldwide. The subcontinent of India represents one of the largest populations in the world, yet remains underserved from an aspect of clinical genetics services. In an effort to bridge this gap, the First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and Advances of New Therapeutics was held in Kochi, Kerala, India. These proceedings chronicle this timely and topical international symposium directed at discussing the best practices and therapies for individuals with neurofibromatoses and RASopathies.

AB - The neurofibromatoses, which include neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis, are a group of syndromes characterized by tumor growth in the nervous system. The RASopathies are a group of syndromes caused by germline mutations in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) pathway. The RASopathies include NF1, Noonan syndrome, Noonan syndrome with multiple lentigines, Costello syndrome, cardio-facio-cutaneous syndrome, Legius syndrome, capillary malformation arterio-venous malformation syndrome, and SYNGAP1 autism. Due to their common underlying pathogenetic etiology, all these syndromes have significant phenotypic overlap of which one common feature include a predisposition to tumors, which may be benign or malignant. Together as a group, they represent one of the most common multiple congenital anomaly syndromes estimating to affect approximately one in 1000 individuals worldwide. The subcontinent of India represents one of the largest populations in the world, yet remains underserved from an aspect of clinical genetics services. In an effort to bridge this gap, the First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and Advances of New Therapeutics was held in Kochi, Kerala, India. These proceedings chronicle this timely and topical international symposium directed at discussing the best practices and therapies for individuals with neurofibromatoses and RASopathies.

KW - clinical trial

KW - neurofibromatoses

KW - RASopathy

KW - signal transduction pathway

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85063366019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063366019&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.61125

DO - 10.1002/ajmg.a.61125

M3 - Article

C2 - 30908877

AN - SCOPUS:85063366019

VL - 179

SP - 1091

EP - 1097

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 6

ER -